Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Chief Financial Officer | November 03, 2020 | November 04, 2020 |
| Guardant Health, Inc.GH · Entity 3238 | Chief Financial Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date November 03, 2020 · Filed November 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,343 |
Ending reported balance
After 2020-11-03 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2020-11-03 · Exercise / conversion · Acquired 3,333 · Balance 113,610 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 2 · 2020-11-03 · Exercise / conversion · Acquired 12,667 · Balance 126,277 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 3 · 2020-11-03 · Exercise / conversion · Acquired 1,168 · Balance 127,445 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 4 · 2020-11-03 · Exercise / conversion · Acquired 4,167 · Balance 131,612 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 5 · 2020-11-03 · Exercise / conversion · Acquired 3,750 · Balance 135,362 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 6 · 2020-11-03 · Exercise / conversion · Acquired 555 · Balance 135,917 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 7 · 2020-11-03 · Sale · Disposed 32,574 · Balance 103,343 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.00 to $48.85, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2027-04-21 | Direct | 6,667 |
Reported balance
After 2020-11-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-03 · Exercise / conversion · Disposed 3,333 · Balance 6,667 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3: 1/4th of the shares subject to the option vested on April 21, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.17 · Expires 2029-02-04 | Direct | 19,333 |
Reported balance
After 2020-11-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-03 · Exercise / conversion · Disposed 12,667 · Balance 19,333 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4: 1/4th of the shares subject to the option vested on February 4, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.31 · Expires 2028-01-19 | Direct | 4,963 |
Reported balance
After 2020-11-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-03 · Exercise / conversion · Disposed 1,168 · Balance 4,963 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 · Expires 2028-06-29 | Direct | 21,875 |
Reported balance
After 2020-11-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-03 · Exercise / conversion · Disposed 4,167 · Balance 21,875 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2027-10-27 | Direct | 13,125 |
Reported balance
After 2020-11-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-11-03 · Exercise / conversion · Disposed 3,750 · Balance 13,125 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7: 1/4th of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2027-09-01 | Direct | 1,667 |
Reported balance
After 2020-11-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-11-03 · Exercise / conversion · Disposed 555 · Balance 1,667 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8: 50% of the shares subject to the option vested on September 1, 2018 and 1/72nd of the shares subject to the option vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.00 to $48.85, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
F3: 1/4th of the shares subject to the option vested on April 21, 2018 and 1/48th of the shares subject to the option vest monthly thereafter.
F4: 1/4th of the shares subject to the option vested on February 4, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F5: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F6: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F7: 1/4th of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter.
F8: 50% of the shares subject to the option vested on September 1, 2018 and 1/72nd of the shares subject to the option vest monthly thereafter.
Guardant Health, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,182 |
Ending reported balance
After 2026-10-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 2,085 · Balance 53,901 Row 2 · 2026-10-01 · Exercise / conversion · Acquired 3,324 · Balance 57,225 Row 3 · 2026-10-01 · Exercise / conversion · Acquired 1,871 · Balance 59,096 Row 4 · 2026-10-01 · Tax withholding · Disposed 3,914 · Balance 55,182 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-01 · Exercise / conversion · Disposed 2,085 · Balance 0 F2: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,296 |
Reported balance
After 2026-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-01 · Exercise / conversion · Disposed 3,324 · Balance 13,296 F4: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,222 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 1,871 · Balance 11,222 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,190 | $107.26 | $127,642.38 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 14 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,052 F11 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.010 to $107.390. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,284 | $106.70 | $350,408.38 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 13 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,242 F10 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.935 to $106.925. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 5,027 | $103.96 | $522,611.44 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 12 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,526 F9 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.720 to $104.510. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 2,533 | $103.24 | $261,509.20 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 11 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,553 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.720 to $103.710. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 8,774 | $102.11 | $895,931.57 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 10 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,086 F8 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.715 to $102.670. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,267 | $101.46 | $331,482.89 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 9 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,860 F7 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.710 to $101.700. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 5,568 | $106.68 | $594,018.18 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 8 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,127 F6 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.420 to $106.980. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 250 | $105.82 | $26,454.00 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 7 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,695 F5 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.415 to $106.390. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 11,978 | $103.96 | $1,245,252.04 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 6 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,945 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.720 to $104.440. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 7,567 | $103.26 | $781,394.15 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 5 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,923 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.720 to $103.710. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 22,891 | $102.11 | $2,337,301.58 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 4 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,490 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.715 to $102.690. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 8,033 | $101.42 | $814,735.78 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,381 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.715 to $101.705. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 26,905 | $28.37 | $763,294.85 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 29,382 | $32.86 | $965,492.52 |
DisclosureSEC source: 0001702824-25-000008 · wk-form4_1765247822.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:04 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 13,097 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001702824-25-000006 · wk-form4_1759449852.xml · derivative · entry 5 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,592 Underlying: Common Stock · 13,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vests on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:04 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,084 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001702824-25-000006 · wk-form4_1759449852.xml · derivative · entry 4 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,337 Underlying: Common Stock · 2,084 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:04 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 7,695 | $62.65 | $482,091.75 |
DisclosureSEC source: 0001702824-25-000006 · wk-form4_1759449852.xml · nonDerivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,127 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:04 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 13,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001702824-25-000006 · wk-form4_1759449852.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:04 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001702824-25-000006 · wk-form4_1759449852.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,039 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001702824-25-000004 · wk-form4_1758143621.xml · derivative · entry 5 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,117 Underlying: Common Stock · 2,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024. The remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001702824-25-000004 · wk-form4_1758143621.xml · derivative · entry 4 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,466 Underlying: Common Stock · 1,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on May 9, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on March 15, 2023. The remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,659 | $54.79 | $90,896.61 |
DisclosureSEC source: 0001702824-25-000004 · wk-form4_1758143621.xml · nonDerivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,641 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001702824-25-000004 · wk-form4_1758143621.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001702824-25-000004 · wk-form4_1758143621.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,084 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000215 · wk-form4_1751505603.xml · derivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,421 Underlying: Common Stock · 2,084 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,057 | $50.71 | $53,600.47 |
DisclosureSEC source: 0001576280-25-000215 · wk-form4_1751505603.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,028 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000215 · wk-form4_1751505603.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,039 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000183 · wk-form4_1750118366.xml · derivative · entry 5 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,156 Underlying: Common Stock · 2,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000183 · wk-form4_1750118366.xml · derivative · entry 4 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,699 Underlying: Common Stock · 1,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on May 9, 2022 that vests over a four-year period. 25% of the shares vested on March 15, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,659 | $49.29 | $81,772.11 |
DisclosureSEC source: 0001576280-25-000183 · wk-form4_1750118366.xml · nonDerivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,001 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000183 · wk-form4_1750118366.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000183 · wk-form4_1750118366.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:29 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,084 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000110 · wk-form4_1743629384.xml · derivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,505 Underlying: Common Stock · 2,084 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:29 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,057 | $42.47 | $44,890.79 |
DisclosureSEC source: 0001576280-25-000110 · wk-form4_1743629384.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,388 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:29 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000110 · wk-form4_1743629384.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,039 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000088 · wk-form4_1742333005.xml · derivative · entry 5 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,195 Underlying: Common Stock · 2,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000088 · wk-form4_1742333005.xml · derivative · entry 4 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,932 Underlying: Common Stock · 1,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on May 9, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on March 15, 2023 and the remaining 75% of the shares vest in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,659 | $42.89 | $71,154.51 |
DisclosureSEC source: 0001576280-25-000088 · wk-form4_1742333005.xml · nonDerivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,361 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000088 · wk-form4_1742333005.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000088 · wk-form4_1742333005.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 20:29 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 22,332 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000066 · wk-form4_1741897745.xml · derivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,332 Underlying: Common Stock · 22,332 shares Expires not disclosed F2 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vests on April 1, 2026, and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 20:29 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantStock Option (Right to Buy) · Derivative | 33,498 | $0.00 Strike: $43.10 | $0.00 |
DisclosureSEC source: 0001576280-25-000066 · wk-form4_1741897745.xml · derivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,498 Underlying: Common Stock · 33,498 shares Expires 2035-03-12 F1 · derivative.exercise_date: This represents a stock option award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vests on April 1, 2026, and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 7,108 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000050 · wk-form4_1741129648.xml · derivative · entry 4 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,220 Underlying: Common Stock · 7,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a performance-based restricted stock unit award granted on February 26, 2024, that a performance metric was achieved and that 33% of the shares subject to such award vested on March 1, 2025. The remaining 67% of the shares vest over the following two years, with 33% of the shares subject to the award vesting on January 1, 2026, and 34% of the shares subject to the award vesting on January 1, 2027. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,537 | $42.55 | $107,949.35 |
DisclosureSEC source: 0001576280-25-000050 · wk-form4_1741129648.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,748 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 7,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000050 · wk-form4_1741129648.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 6,617 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000034 · wk-form4_1738707184.xml · derivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,617 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Not applicable for Performance-Based Restricted Stock Units. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,361 | $46.98 | $110,919.78 |
DisclosureSEC source: 0001576280-25-000034 · wk-form4_1738707184.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,177 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the performance-based restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 6,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000034 · wk-form4_1738707184.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 3,309 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000022 · wk-form4_1737064977.xml · derivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock unit vested 25% of the shares subject to such award on January 15, 2022, and the remaining 75% of the shares subject to such award vests in substantially equal installments on each anniversary of January 15, 2022, during the three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,305 | $37.50 | $48,937.50 |
DisclosureSEC source: 0001576280-25-000022 · wk-form4_1737064977.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,921 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.